The Food and Drug Administration is considering guidelines that would speed the approval process for new anti-obesity drugs, the Wall Street Journal reported Monday.
Under an original proposal developed last fall, the newspaper reported, two years of human testing would be required before approval of such drugs.
But more recently, a panel of scientists proposed requiring only one year of human testing on anti-obesity drugs and easing the requirement for evidence that the drugs lower the risk of heart disease and other problems linked to obesity.
The FDA appears likely to adopt the newer, less stringent requirements, the paper said.
The new drugs, based on new understanding of metabolic abnormalities, are expected to work better and have fewer side effects than older drugs.